



BSN DANA DIVIDEN AL-IFRAH



Fund Objective

The Fund seeks to provide consistent income* by investing in Shariah-compliant equities with attractive dividend** yield and/or potential dividend yield.

*Note: Distribution of income will be done by way of reinvestment into additional Units.

**Note: "Attractive dividend" refers to stocks of companies which have provided an average gross dividend of at least 3% for the past 3 years from the latest financial year.

Market Review

The FBM EMAS Shariah Index declined 3.7% in August 2024. Finance and Plantation were the best performing sectors during the month, gaining 8.5% and 1.5% respectively. On the other hand, Technology, Construction and Property was the worst performing sector, losing 14.9%, 10.6% and 9.1% respectively.

Fund Details


Launch Date	12 September 2012
Fund Size as of 30 August 2024	264.974 million units
Trustee	AmanahRaya Trustees Berhad
Minimal Initial Investment	RM500.00
Performance Benchmark	FTSE Bursa Malaysia EMAS Shariah Index (FBMSHA)
Sales Charge	Up to 4.5% of NAV/unit
Annual Management Fee	1.5% p.a of NAV
Annual Trustee Fee	0.06% p.a of NAV
Redemption Fee	Nil
Switching Fee	Nil
Price as of 30 August 2024 (RM)	0.1782

Dividend Distribution History (Last 5 Years)

Year	Gross Distribution/Unit (Sen)
2020	Nil
2021	Nil
2022	Nil
2023	Nil
2024 (Interim)	0.75

Source: Permodalan BSN Berhad

Fund Performance Analysis



Annual Total Return					
	1 year	3 years	5 years	10 years	Since Inception
Al-Ifrah	5.59	0.94	2.02	-12.36	1.56
FBMSHA	12.51	-3.64	3.14	-7.06	7.01

Source: All performance figures have been verified by Novagni Analytics and Advisory Sdn Bhd


Top 5 Holdings (as at 30 August 2024)

Stocks	
Tenaga Nasional Berhad	
Uchi Technologies Berhad	
Ta Ann Holdings Berhad	
Petronas Gas Berhad	
IHH Healthcare Berhad	

Top 5 Sector Allocations (as at 30 August 2024)

Sector	% NAV
Utilities	10.53
Property	8.84
Financial Services	8.47
Consumer Products & Services	8.38
Technology	7.38

Asset Allocation



DISCLAIMER:

Based on the fund's portfolio returns as at 10 September 2024, the Volatility Factor (VF) for this fund is 6.76 and is classified as "Low". (Source: Lipper). "Low" includes funds with VF that are above 4.91 but not more than 8.975 (source: Lipper). The VF means there is a possibility for the Fund in generating an upside return or downside return around this VF. The Volatility Class (VC) is assigned by Lipper based on quintile ranks of VF for qualified funds. VF is subject to monthly revision and VC will be revised every six months or other interval as advised by FIMM. The Fund's portfolio may have changed since this date and there is no guarantee that the Fund will continue to have the same VF or VC in the future. Presently, only funds launched in the market for at least 36 months will display the VF and its VC. The VC referred to was dated 31 August 2024.

A Product Highlights Sheet ("PHS") highlighting the key features and risks of BSN Dana Dividen Al-Ifrah (the "Fund") is available and investors have the right to request for a copy of it. Investors are advised to obtain, read and understand the contents of the Master Prospectus dated 18 September 2023 ("Master Prospectus") as well as the PHS before investing. The Master Prospectus has been registered and the PHS have been lodged with the Securities Commission Malaysia ("SC"), who takes no responsibility for its contents. Any issue of units to which the Master Prospectus related will only made upon receipt of the completed application form referred to in and accompanying the Master Prospectus. There are fees and charges involved and you are advised to consider them before investing in the Fund. Price of units and distribution payable, if any, may go down as well as up. Past performance is not an indication of future performance and income distributions are not guaranteed. Investments in the Fund carry risks and the general risks as well as the specific risks of the Fund is elaborated in the Master Prospectus. The Master Prospectus and PHS can be obtained from Permodalan BSN Berhad and / or any of the authorised distributors. If you plan to purchase units of the Fund via loan financing, you are advised to read and understand the contents of the "Unit Trust Loan Financing Disclosure Statement" before proceed to financing. The fund factsheet has not been reviewed nor recommended by the SC. As such, the SC shall not be liable for the contents.